Lanthanum carbonate AnorMED

Current Opinion in Cardiovascular, Pulmonary and Renal Investigational Drugs

Volumn 2, Issue 4, 2000, Pages 372-377

  Locatelli, F ^a   D'Amico, M ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM CHLORIDE; ALUMINUM DERIVATIVE; ALUMINUM HYDROXIDE; CALCIUM DERIVATIVE; CARBONIC ACID; LAMBDA; LANTHANUM; LANTHANUM CHLORIDE; LIGAND; MAGNESIUM DERIVATIVE; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG INHIBITION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MICROCYTIC ANEMIA; NAUSEA; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; REVIEW; SECONDARY HYPERPARATHYROIDISM; STRUCTURE ACTIVITY RELATION; VOMITING;

EID: 0033846827     PISSN: 14648482     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Shire focuses on 'virtual integration'
2. Shire Pharmaceutical Group plc
3. Company Brochure Shire Pharmaceuticals
4. Annual Review 95/96
5. Major achievements by Shire in its tenth anniversary year. Four projects advanced to the next development phase
6. Shire Pharmaceuticals Group plc, Annual Review 1995/1996
7. Shire Pharmaceuticals Group plc placing by Panmure Gordon and Co Ltd
8. Shire Pharmaceuticals Group - Panmure Gordon analyst report March 1996
9. Positive progress in Shire's development portfolio
10. Clinical trial results
11. Shire to enter Phase II studies with Lambda
12. Shire to boost R and D after Pharmavene deal
13. Shire Pharmaceuticals Group plc: Excellent commercial and research and development progress
14. Shire's prospects for chronic fatigue syndrome and renal bone disorder
15. Shire to double UK product sales
16. A low-risk strategy for drug development
17. Shire buys US marketing base.....new products, and R and D
18. Shire Pharmaceuticals Group plc Preliminary results for the year ended 30 June 1997. A year of significant achievement
19. Nomura: European Biotechnology: A prescription for growth
20. Shire to slim down R and D/product palette
21. Shire Pharmaceuticals Group plc Results for the six months ended 30 June 1998
22. Lanthanum carbonate: A novel non-calcium containing phosphate binder
23. Lanthanum carbonate: A study of absorption in healthy human subjects
24. Lanthanum carbonate an effective inhibitor of phosphate absorption from the intestinal tract
25. Open house presentation - AnorMED Inc
26. Shire Pharmaceuticals Group plc reports STG 6.2 million profit for the nine months ended September 1998
27. Shire Research and Development update; Galantamine update - Lambda enters phase III early
28. Shire reports strong profit growth
29. Lehman Brothers: Healthcare UK and Europe: Pharmabulletin
30. Shire reports positive US phase II results for Lambda
31. AnorMED's drug Lambda will proceed to phase III in US after positive phase II results with kidney failure patients
32. Shire announces continued strong growth in the second quarter 1999
33. Lehman Brothers: Healthcare UK and Europe: Pharmabulletin
34. Lehman Brothers: Pharmaceuticals United Kingdom: Shire Pharmaceuticals and Medeva
35. Product portfolio - 1999
36. Corporate profile
37. First Quarter Report - AnorMED
38. BioPartnering - AnorMED Inc
39. Shire's third quarter results for 1999 show continued growth
40. AnorMED's drug Lambda enters phase III in US
41. BioPartnering - Shire Pharmaceuticals Group plc
42. Annual Report 1999 - AnorMED Inc
43. Shire Pharmaceuticals Group plc
44. Shire's revenues up 30%; Operating profit (before exceptionals) up 154%
45. Lehman Brothers Pharmabulletin
46. Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy
47. The preferred phosphate binder in dialysis patients
48. Phosphate binders on iron basis: A new perspective?
49. Safety of an investigational phosphate binder (lanthanum carbonate) in hemodialysis patients
50. Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis
51. Hyperphosphataemia - a silent killer of patients with renal failure
52. Association of serum phosphorous and calcium x phosphate product with mortality risk in chronic haemodialysis patients: A national study
53. Fracturing dialysis osteodystrophy and dialysis encephalopathy
54. Reduction of dietary phosphorous absorption by phosphorous binders
55. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorous and parathyroid hormone. The RenaGel Study Group
56. A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorous absorption
57. Lanthanum carbonate: A novel non-calcium containing phosphate binder in CAPD patients
58. Combined Report on Regular Dialysis and Transplantation in Europe, XX, 1989
59. 1999 Annual Report - Shire Pharmaceuticals Group Plc